NDAORALSOLUTION
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Benylin is a combination oral solution containing diphenhydramine hydrochloride (first-generation antihistamine) and pseudoephedrine hydrochloride (decongestant) indicated for symptomatic relief of cold and allergy symptoms. This fixed-dose combination targets multiple symptom pathways simultaneously to provide broad relief of nasal congestion, sneezing, runny nose, and other upper respiratory discomfort.
Pre-Launch
Pre-launch stage indicates limited current team expansion; career opportunity depends on successful regulatory approval and market entry timing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Joining the Benylin team pre-launch offers early exposure to product launch strategy, market positioning, and OTC commercialization in a highly competitive segment. Career growth potential depends on successful approval and market penetration; roles will be primarily commercial and regulatory rather than clinical.
Brand ManagerField Sales Representative
Worked on BENYLIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.